From Germany: NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) response and outcomes, according to a study published online April 24 in the Journal of Clinical Oncology.
Niklas Klumper, M.D., from University Hospital Bonn in Germany, and colleagues examined the predictive value of NECTIN4 copy number variations (CNVs) in a multicenter EV-treated mUC patient cohort (108 patients). The correlations between CNVs with membranous NECTIN4 protein expression, EV treatment responses, and outcomes were examined. In addition, the prognostic value of NECTIN4 CNVs was measured in metastatic biopsies of 103 patients with non-EV-treated mUC. The Cancer Genome Atlas (TCGA) datasets, with 10,712 patients across 32 cancer types, were also queried for NECTIN4 CNVs.
Source: Advances and More licensed by HealthDay
